Integra LifeSciences Holdings
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Integra LifeSciences Holdings's revenues will grow 4.6% and EPS will wither 0.0%.
The average estimate for revenue is $211.4 million. On the bottom line, the average EPS estimate is $0.77.
Revenue details
Last quarter, Integra LifeSciences Holdings tallied revenue of $210.2 million. GAAP reported sales were 8.7% higher than the prior-year quarter's $193.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
Last quarter, non-GAAP EPS came in at $0.74. GAAP EPS of $0.30 for Q2 were much higher than the prior-year quarter's $0.02 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Recent performance
For the preceding quarter, gross margin was 64.5%, 40 basis points better than the prior-year quarter. Operating margin was 13.0%, 170 basis points worse than the prior-year quarter. Net margin was 4.1%, 370 basis points better than the prior-year quarter.
Looking ahead
The full year's average estimate for revenue is $834.5 million. The average EPS estimate is $3.04.
Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 158 members out of 170 rating the stock outperform, and 12 members rating it underperform. Among 54 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 53 give Integra LifeSciences Holdings a green thumbs-up, and one give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Integra LifeSciences Holdings is outperform, with an average price target of $42.31.
- Add Integra LifeSciences Holdings to My Watchlist.